<DOC>
	<DOCNO>NCT02807961</DOCNO>
	<brief_summary>This first study human ELX-02 , advance synthetic aminoglycoside optimized translational read-through drug ( TRID ) treatment genetic condition cause nonsense . mutation . This classical Phase 1a study design randomize , double-blinded , placebo-controlled , single dose escalation evaluate safety , tolerability pharmacokinetics ELX-02 healthy adult volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics ELX-02 Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<criteria>Subjects must meet follow criterion participate study . 1 . Be able willing provide write Informed Consent indicate subject inform pertinent aspect study . 2 . Be willing able comply schedule visit , treatment plan , laboratory test , study procedure . 3 . Healthy female subject and/or male subject , time screening , age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include BP pulse rate measurement , 12lead electrocardiogram ( ECG ) clinical laboratory test . 4 . Female subject nonchildbearing potential must meet least one follow criterion : Achieved postmenopausal status , define follow : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; postmenopausal status confirm serum folliclestimulating hormone level ; Have undergone document hysterectomy and/or bilateral oophorectomy ; Have medically confirm ovarian failure . All female subject ( include female tubal ligation ) consider childbearing potential Female subject childbearing potential partner male subject must use highly effective method contraception 14 day 28 day drug administration . These include : Abstention sexual intercourse ; Established use oral , inserted , injected , implanted transdermal hormonal method contraception ( provide subject plan remain treatment throughout entire study use hormonal contraceptive adequate period time ensure effectiveness ) . Coppercontaining intrauterine device . ; Female barrier contraceptive ( e.g. , female condom , diaphragm spermicide ) plus male condom . 5 . All female subject ( include female tubal ligation ) consider childbearing potential may enrol negative pregnancy test Screening Day 1 agree use reliable method contraception 14 day 28 day study . Female subject childbearing potential must agree undergo repeated pregnancy test . 6 . Male subject must willing use highly effective method contraception . They must agree use condom consistently correctly , course study 28 day drug administration . These include undergone vasectomy abstain sexual intercourse . 7 . Be medication potential impair renal function , e.g. , nonsteroidal antiinflammatory drug , ototoxic potential , e.g. , quinine salicylate . 8 . Nonsmoking use tobacco nicotine product ( declaration ) period least 6 month prior screen visit . 9 . Normal renal function ( glomerular filtration rate &gt; 70 mL/min ) base creatinine plasma concentration Modification Diet Renal Disease equation estimate glomerular filtration rate . 10 . Negative human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) serology test screen . 11 . No history alcohol DOA . Negative urine test drug abuse ( DOA ) alcohol breath test Screening Day 1 . 12 . No personal familial history ( current ) hearing loss , tinnitus , vertigo , imbalance unsteadiness . 13 . No finding baseline audiometry vestibular assessment test . 14 . Body Mass Index ( BMI ) 19.0 30.0 kg/m2 ( extremes include ) ; total body weight &gt; 50 kg ( 110 lb ) . Subjects meet follow criterion eligible study : 1 . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject Sponsor employee directly involve conduct study . 2 . Participation another clinical trial within 6 month prior dose ( calculate previous study 's last dosing day ) . If previous trial involve agent delayed effect prolong metabolism , 12 month interval require . 3 . Evidence history clinically relevant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy ) . This include acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational drug administration may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study . 4 . A positive urine drug screen ( cannabinoids , amphetamine , benzodiazepine , opiate ) . 5 . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 150 mL [ 5 ounce ] wine 360 mL [ 12 ounce ] beer 45 mL [ 1.5 ounce ] hard liquor ) within 6 month Screening . 6 . Screening supine BP ≥140 mm Hg ( systolic ) ≥90 mm Hg ( diastolic ) , follow least 5 min supine rest . 7 . Screening supine 12lead ECG demonstrate QTcF &gt; 450 msec men &gt; 470 msec woman , QRS interval &gt; 120 msec . 8 . Subjects ANY abnormality clinical laboratory test screen , consider study physician clinically relevant . In particular , subject alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) total bilirubin ≥1.5 upper limit normal exclude . Abnormal test may confirm single repeat . 9 . Pregnant breastfeed female subject ; male subject able father child female subject childbearing potential unwilling unable use highly effective method contraception outline protocol duration study least 14 day 28 day last dose study medication . 10 . Use prescription nonprescription drug dietary supplement within 30 day 5 halflives ( whichever longer ) prior administration study medication . As exception , acetaminophen/paracetamol may use dos ≤2 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval Sponsor . 11 . Herbal supplement discontinue least 30 day prior administration study medication . 12 . Subjects donate blood receive blood plasma derivative three month precede study medication administration . 13 . Unwilling unable comply restriction describe protocol . 14 . Known relevant allergy hypersensitivity drug and/or excipients investigational drug . 15 . Subjects inability communicate well Investigator clinical site staff ( e.g. , language problem , poor mental development ) . 16 . Subjects acute medical situation ( e.g. , acute infection ) within 48 h study start , consider significance Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Translational read</keyword>
</DOC>